On December 8, 2022, the Board of Directors of Philip Morris International Inc. approved the appointment of Jorge Insuasty as the full-time President, Vectura Fertin Pharma, effective January 1, 2023. In connection with this appointment, Mr. Insuasty will no longer also serve as Chief Life Sciences Officer of the Company and Badrul Chowdhury, the Company’s Chief Life Sciences Officer, Smoke-Free Products, will report directly to the Company’s Chief Executive Officer, Jacek Olczak. Mr. Insuasty will continue to report directly to Mr. Olczak, and no changes were made to Mr. Insuasty’s compensation arrangements in connection with the change in his role.

As part of the Company’s regional restructuring and as previously disclosed in the Company’s Current Report on Form 8-K filed on November 25, 2022, Frederic de Wilde, currently President, European Union Region, will be appointed President, South and Southeast Asia (SSEA), Commonwealth of Independent States (CIS), Middle East and Africa (MEA) Region. In connection with the foregoing, on December 8, 2022, the Board approved the following changes to Mr. de Wilde’s compensation, to be effective on his appointment.